Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Prenatal Marijuana Use by Self-Report and Umbilical Cord Sampling in a State With Marijuana Legalization.

Metz TD, Silver RM, McMillin GA, Allshouse AA, Jensen TL, Mansfield C, Heard K, Kinney GL, Wymore E, Binswanger IA.

Obstet Gynecol. 2019 Jan;133(1):98-104. doi: 10.1097/AOG.0000000000003028.

PMID:
30531577
2.

Quantitation of Ethyl-β-D-Glucuronide in Human Umbilical Cord Tissue by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS).

Wabuyele SL, McMillin GA.

Methods Mol Biol. 2019;1872:223-236. doi: 10.1007/978-1-4939-8823-5_21.

PMID:
30350294
3.

Detection of In Utero Cannabis Exposure in Umbilical Cord Tissue by a Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method.

Wu F, Jensen TL, McMillin GA.

Methods Mol Biol. 2019;1872:211-222. doi: 10.1007/978-1-4939-8823-5_20.

PMID:
30350293
4.

Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine.

Ji Y, Si Y, McMillin GA, Lyon E.

Expert Rev Mol Diagn. 2018 May;18(5):411-421. doi: 10.1080/14737159.2018.1461561. Epub 2018 Apr 23.

PMID:
29634383
5.

Detection of Drug-Exposed Newborns.

Wabuyele SL, Colby JM, McMillin GA.

Ther Drug Monit. 2018 Apr;40(2):166-185. doi: 10.1097/FTD.0000000000000485. Review.

PMID:
29419722
6.
7.

Development of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Four Cannabinoids in Umbilical Cord Tissue.

Wu F, Scroggin TL, Metz TD, McMillin GA.

J Anal Toxicol. 2018 Jan 1;42(1):42-48. doi: 10.1093/jat/bkx078.

PMID:
28977394
8.

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.

Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodríguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS.

JAMA. 2017 Sep 26;318(12):1115-1124. doi: 10.1001/jama.2017.11469. Erratum in: JAMA. 2018 Mar 27;319(12 ):1281.

9.

Stability of 21 Cocaine, Opioid and Benzodiazepine Drug Analytes in Spiked Meconium at Three Temperatures.

Wu F, Marin SJ, McMillin GA.

J Anal Toxicol. 2017 Apr 1;41(3):196-204. doi: 10.1093/jat/bkw113.

PMID:
27881622
10.

Erratum to: Use of signals and systems engineering to improve the safety of warfarin initiation.

Hyun G, Li J, Bass AR, Mohapatra A, Woller SC, Lin H, Eby C, McMillin GA, Gage BF.

J Thromb Thrombolysis. 2016 Nov;42(4):534. No abstract available.

PMID:
27557560
11.

Use of signals and systems engineering to improve the safety of warfarin initiation.

Hyun G, Li J, Bass AR, Mohapatra A, Woller SC, Lin H, Eby C, McMillin GA, Gage BF.

J Thromb Thrombolysis. 2016 Nov;42(4):529-33. doi: 10.1007/s11239-016-1402-z. Erratum in: J Thromb Thrombolysis. 2016 Nov;42(4):534.

12.

Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.

Powers JL, Buys SS, Fletcher D, Melis R, Johnson-Davis KL, Lyon E, Malmberg EM, McMillin GA.

J Clin Pharmacol. 2016 Dec;56(12):1570-1581. doi: 10.1002/jcph.771. Epub 2016 Jun 21.

PMID:
27198207
13.

Development of a liquid chromatography-tandem mass spectrometry method to address the increased utilization of umbilical cord in the assessment of in utero drug exposure.

Haglock-Adler CJ, McMillin GA, Strathmann FG.

Clin Biochem. 2016 Sep;49(13-14):1092-5. doi: 10.1016/j.clinbiochem.2016.04.007. Epub 2016 Apr 27.

PMID:
27131494
14.

Quantitation of Buprenorphine, Norbuprenorphine, Buprenorphine Glucuronide, Norbuprenorphine Glucuronide, and Naloxone in Urine by LC-MS/MS.

Marin SJ, McMillin GA.

Methods Mol Biol. 2016;1383:69-78. doi: 10.1007/978-1-4939-3252-8_8.

PMID:
26660175
15.

Quantitation of Total Buprenorphine and Norbuprenorphine in Meconium by LC-MS/MS.

Marin SJ, McMillin GA.

Methods Mol Biol. 2016;1383:59-68. doi: 10.1007/978-1-4939-3252-8_7.

PMID:
26660174
16.

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.

Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Caudle K, Coulthard SA, Daly AK, Del Tredici A, den Dunnen JT, Drozda K, Everts RE, Flockhart D, Freimuth RR, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, Müller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale RF, van Schaik R, Whirl-Carrillo M, Yeo K, Zanger UM.

Clin Pharmacol Ther. 2016 Feb;99(2):172-85. doi: 10.1002/cpt.280. Epub 2015 Nov 20. Review.

17.

A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays.

McMillin GA, Marin SJ, Johnson-Davis KL, Lawlor BG, Strathmann FG.

Am J Clin Pathol. 2015 Feb;143(2):234-40. doi: 10.1309/AJCPMJKBC6VJA1SP.

PMID:
25596249
18.

Patterns of Drugs and Drug Metabolites Observed in Meconium: What Do They Mean?

McMillin GA, Wood KE, Strathmann FG, Krasowski MD.

Ther Drug Monit. 2015 Oct;37(5):568-80. doi: 10.1097/FTD.0000000000000181.

PMID:
25565668
19.

Retrospective analysis of the diagnostic yield of newborn drug testing.

Wood KE, Sinclair LL, Rysgaard CD, Strathmann FG, McMillin GA, Krasowski MD.

BMC Pregnancy Childbirth. 2014 Jul 29;14:250. doi: 10.1186/1471-2393-14-250.

20.

Reference interval determination for anabasine: a biomarker of active tobacco use.

Suh-Lailam BB, Haglock-Adler CJ, Carlisle HJ, Ohman T, McMillin GA.

J Anal Toxicol. 2014 Sep;38(7):416-20. doi: 10.1093/jat/bku059. Epub 2014 Jun 17.

PMID:
24939383
21.

Meconium drug testing in multiple births in the USA.

Wood KE, Krasowski MD, Strathmann FG, McMillin GA.

J Anal Toxicol. 2014 Sep;38(7):397-403. doi: 10.1093/jat/bku061. Epub 2014 Jun 13.

PMID:
24927721
22.

Advances in anti-epileptic drug testing.

Krasowski MD, McMillin GA.

Clin Chim Acta. 2014 Sep 25;436:224-36. doi: 10.1016/j.cca.2014.06.002. Epub 2014 Jun 10. Review.

PMID:
24925169
23.

Demystifying analytical approaches for urine drug testing to evaluate medication adherence in chronic pain management.

McMillin GA, Slawson MH, Marin SJ, Johnson-Davis KL.

J Pain Palliat Care Pharmacother. 2013 Dec;27(4):322-39. doi: 10.3109/15360288.2013.847889. Epub 2013 Oct 22. Review.

PMID:
24147959
24.

Detection of neonatal drug exposure using umbilical cord tissue and liquid chromatography time-of-flight mass spectrometry.

Marin SJ, Metcalf A, Krasowski MD, Linert BS, Clark CJ, Strathmann FG, McMillin GA.

Ther Drug Monit. 2014 Feb;36(1):119-24. doi: 10.1097/FTD.0b013e3182a0d18c.

PMID:
24061447
25.

Detection of in utero marijuana exposure by GC-MS, ultra-sensitive ELISA and LC-TOF-MS using umbilical cord tissue.

Chittamma A, Marin SJ, Williams JA, Clark C, McMillin GA.

J Anal Toxicol. 2013 Sep;37(7):391-4. doi: 10.1093/jat/bkt052. Epub 2013 Jul 10.

PMID:
23843423
26.

Simultaneous UPLC-MS/MS assay for the detection of the traditional antipsychotics haloperidol, fluphenazine, perphenazine, and thiothixene in serum and plasma.

Juenke JM, Brown PI, Urry FM, Johnson-Davis KL, McMillin GA.

Clin Chim Acta. 2013 Aug 23;423:32-4. doi: 10.1016/j.cca.2013.04.014. Epub 2013 Apr 23.

PMID:
23618971
27.

Commentary.

McMillin GA.

Clin Chem. 2013 Apr;59(4):616. doi: 10.1373/clinchem.2012.191122. No abstract available.

28.

Evaluation of the NexScreen and DrugCheck Waive RT urine drug detection cups.

Lin CN, Nelson GJ, McMillin GA.

J Anal Toxicol. 2013 Jan-Feb;37(1):30-6. doi: 10.1093/jat/bks087. Epub 2012 Nov 9.

PMID:
23144203
29.

Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity.

Melis R, Lewis T, Millson A, Lyon E, McMillin GA, Slev PR, Swensen J.

Genet Test Mol Biomarkers. 2012 Sep;16(9):1111-4. doi: 10.1089/gtmb.2012.0115. Epub 2012 Aug 22.

PMID:
22913531
30.

Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation.

Borgman MP, Pendleton RC, McMillin GA, Reynolds KK, Vazquez S, Freeman A, Wilson A, Valdes R Jr, Linder MW.

Thromb Haemost. 2012 Sep;108(3):561-9. doi: 10.1160/TH12-03-0159. Epub 2012 Jul 26.

31.

Sensitive UPLC-MS-MS assay for 21 benzodiazepine drugs and metabolites, zolpidem and zopiclone in serum or plasma.

Marin SJ, Roberts M, Wood M, McMillin GA.

J Anal Toxicol. 2012 Sep;36(7):472-6. doi: 10.1093/jat/bks059. Epub 2012 Jul 23.

PMID:
22833647
32.

Unresolved discrepancies between cannabinoid test results for infant urine.

Barakauskas VE, Davis R, Krasowski MD, McMillin GA.

Clin Chem. 2012 Sep;58(9):1364-7. doi: 10.1373/clinchem.2012.190090. Epub 2012 Jul 24.

33.

Rapid screening for 67 drugs and metabolites in serum or plasma by accurate-mass LC-TOF-MS.

Marin SJ, Hughes JM, Lawlor BG, Clark CJ, McMillin GA.

J Anal Toxicol. 2012 Sep;36(7):477-86. doi: 10.1093/jat/bks061. Epub 2012 Jul 15.

PMID:
22802572
34.

Quantification of tricyclic antidepressants using UPLC-MS/MS.

Johnson-Davis KL, Juenke JM, Davis R, McMillin GA.

Methods Mol Biol. 2012;902:175-84. doi: 10.1007/978-1-61779-934-1_16.

PMID:
22767118
35.

Method comparison of the Ortho Vitros Fusion 5,1 chemistry analyzer and the Roche COBAS Integra 400 for urine drug screen testing in the emergency department.

Johnson-Davis KL, Thompson CD, Clark CJ, McMillin GA, Lehman CM.

J Anal Toxicol. 2012 Jun;36(5):345-8. doi: 10.1093/jat/bks028.

PMID:
22582270
36.

Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry.

McMillin GA, Davis R, Carlisle H, Clark C, Marin SJ, Moody DE.

J Anal Toxicol. 2012 Mar;36(2):81-7. doi: 10.1093/jat/bkr020.

PMID:
22337776
37.

Analytical performance of a new liquid chromatography/tandem mass spectrometric method for determination of everolimus concentrations in whole blood.

McMillin GA, Johnson-Davis K, Dasgupta A.

Ther Drug Monit. 2012 Apr;34(2):222-6. doi: 10.1097/FTD.0b013e318246d515. Erratum in: Ther Drug Monit. 2012 Aug;34(4):485.

PMID:
22322402
38.

Pediatric reference intervals for serum copper and zinc.

Lin CN, Wilson A, Church BB, Ehman S, Roberts WL, McMillin GA.

Clin Chim Acta. 2012 Mar 22;413(5-6):612-5. doi: 10.1016/j.cca.2011.12.005. Epub 2011 Dec 13.

PMID:
22192859
39.

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.

Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF.

Thromb Haemost. 2012 Feb;107(2):232-40. doi: 10.1160/TH11-06-0388. Epub 2011 Dec 21.

40.

Performance characteristics and patient comparison of the ARK Diagnostics levetiracetam immunoassay with an ultra-high performance liquid chromatography with tandem mass spectrometry detection method.

Juenke JM, McGraw JP, McMillin GA, Johnson-Davis KL.

Clin Chim Acta. 2012 Feb 18;413(3-4):529-31. doi: 10.1016/j.cca.2011.11.018. Epub 2011 Nov 25. No abstract available.

PMID:
22137980
41.

Current challenges in personalizing warfarin therapy.

McMillin GA, Vazquez SR, Pendleton RC.

Expert Rev Clin Pharmacol. 2011 May;4(3):349-62. doi: 10.1586/ecp.11.15. Review.

PMID:
22114781
42.

Unexplained hemolytic anemia with multiorgan failure.

Raval G, Straughen JE, McMillin GA, Bornhorst JA.

Clin Chem. 2011 Nov;57(11):1485-8. doi: 10.1373/clinchem.2010.160119. No abstract available.

43.

Rapid and specific quantification of ethylene glycol levels: adaptation of a commercial enzymatic assay to automated chemistry analyzers.

Juenke JM, Hardy L, McMillin GA, Horowitz GL.

Am J Clin Pathol. 2011 Aug;136(2):318-24. doi: 10.1309/AJCPOB9YPQIYKGLJ.

PMID:
21757606
44.

Evaluation of the Abbott ARCHITECT i2000 sirolimus assay and comparison with the Abbott IMx sirolimus assay and an established liquid chromatography-tandem mass spectrometry method.

Johnson-Davis KL, De S, Jimenez E, McMillin GA, De BK.

Ther Drug Monit. 2011 Aug;33(4):453-9. doi: 10.1097/FTD.0b013e3182263981.

PMID:
21743377
45.

A comparison of two FDA approved lamotrigine immunoassays with ultra-high performance liquid chromatography tandem mass spectrometry.

Juenke JM, Miller KA, Ford MA, McMillin GA, Johnson-Davis KL.

Clin Chim Acta. 2011 Sep 18;412(19-20):1879-82. doi: 10.1016/j.cca.2011.06.009. Epub 2011 Jun 15.

PMID:
21693111
46.

Performance characteristics of the ARK diagnostics gabapentin immunoassay.

Juenke JM, Wienhoff KA, Anderson BL, McMillin GA, Johnson-Davis KL.

Ther Drug Monit. 2011 Aug;33(4):398-401. doi: 10.1097/FTD.0b013e318220bb65.

PMID:
21654348
47.

Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.

Do EJ, Lenzini P, Eby CS, Bass AR, McMillin GA, Stevens SM, Woller SC, Pendleton RC, Anderson JL, Proctor P, Nunley RM, Davila-Roman V, Gage BF.

Pharmacogenomics J. 2012 Oct;12(5):417-24. doi: 10.1038/tpj.2011.18. Epub 2011 May 24.

48.
49.

An automated method for supporting busulfan therapeutic drug monitoring.

Juenke JM, Miller KA, McMillin GA, Johnson-Davis KL.

Ther Drug Monit. 2011 Jun;33(3):315-20. doi: 10.1097/FTD.0b013e318214cd75.

PMID:
21544019
50.

Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infiniti™ and Luminex CYP2C19 panels.

Lee CC, McMillin GA, Babic N, Melis R, Yeo KT.

Clin Chim Acta. 2011 May 12;412(11-12):1133-7. doi: 10.1016/j.cca.2011.03.001. Epub 2011 Mar 6.

PMID:
21385571

Supplemental Content

Loading ...
Support Center